2023-02-22

Press Release: BD Onclarity™ HPV Assay Receives FDA Approval for Use with Both BD SurePath™ Liquid-based Pap Test and Hologic ThinPrep® Pap Test

BD Onclarity HPV Assay

The BD Onclarity™ HPV Assay has received FDA Approval for use with both BD SurePath™ Liquid-based Pap Test and Hologic ThinPrep® Pap Test, which expands access to the HPV test that more precisely identifies patients’ risk for cervical cancer.

“When more people with a cervix are better able to manage their health through more accurate and precise testing, we are taking another step forward toward eliminating cervical cancer in our lifetimes,” said Dr. Jeff Andrews, Vice President of Medical Affairs for BD.

ThinPrep is a trademark of Hologic, Inc.

Latest resources

Discover our latest articles, webinars, press releases and updates in women's health.

James Walker
MLO Online: COVID-19’s impact on testing practices for STIs
Guidelines: ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors
Cervical Cancer | Articles & Publications
Guidelines: ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors
BD submits pre-market approval supplement to FDA to enable ThinPrep® Pap Test™ PreservCyt® Solution to be used with the BD Onclarity™ HPV Assay
Cervical Cancer | News & Updates
Press release: BD submits pre-market approval supplement to FDA to enable ThinPrep® Pap Test™ PreservCyt® Solution to be used with the BD Onclarity™ HPV Assay